<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04095715</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190393</org_study_id>
    <nct_id>NCT04095715</nct_id>
  </id_info>
  <brief_title>Anomalies of Dense Platelet Granules</brief_title>
  <acronym>AGRAD</acronym>
  <official_title>Diagnosis of Platelet Dense Granules Anomalies in Unexplained Hemorrhagic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>CENTRE DE REFERENCE DES MALADIES HEMORRAGIQUES CONSTITUTIONNELLES</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to know the overall prevalence of granular deficits and their breakdown by
      type (anomaly of number, content or secretion) in a population of patients with hemorrhagic
      symptomatology after exclusion of other known causes.

      This study consists also to evaluate the association between the presence of a deficit in
      dense granules and (1) the intensity of the hemorrhagic phenotype (hemorrhagic score) (2) the
      nature of hemorrhages (post-operative, spontaneous, atypical...)

      -Evaluate the association between the type of deficit in dense granules and (1) the intensity
      of the hemorrhagic phenotype (hemorrhagic score) (2) the nature of hemorrhages
      (post-operative, spontaneous, atypical...)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be recruited during the exploration visit (v0) or the confirmation/typing visit
      (v1) according to their follow-up.

        -  Exploration visit (v0): inclusion of patients without prior platelet exploration, and
           study of their dense platelet granules.

        -  Confirmation/typing visit (v1): verification of the persistence of anomalies detected in
           patients with an abnormality identified during v0 (no later than 6 months after v0) and
           in patients for whom a dense granules anomaly has already been identified during their
           standard management prior to the start of the study. Completion of complementary
           examinations to complement the typing of the granular anomaly and molecular analysis for
           family cases
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 9, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Platelet response to different agonists</measure>
    <time_frame>Baseline (M0)</time_frame>
    <description>Us of some low-dose agonists such as ADP, epinephrine or collagen, which are particularly susceptible to granular defects, on platelet-rich plasma (PRP) prepared from the patient's blood sample to be explored</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Platelet response to different agonists</measure>
    <time_frame>At 6 months</time_frame>
    <description>Use of some low-dose agonists such as ADP, epinephrine or collagen, which are particularly susceptible to granular defects, on platelet-rich plasma (PRP) prepared from the patient's blood sample to be explored</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Granular Delta content</measure>
    <time_frame>Baseline (M0)</time_frame>
    <description>Dosage of platelet serotonin by measuring platelet serotonin by HPLC.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of ATP</measure>
    <time_frame>Baseline (M0)</time_frame>
    <description>The measurement is based on the principle of bioluminescence with a two-step transformation reaction of luciferin in the presence of luciferase, this reaction requiring the presence of ATP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of ATP</measure>
    <time_frame>At 6 months</time_frame>
    <description>The measurement is based on the principle of bioluminescence with a two-step transformation reaction of luciferin in the presence of luciferase, this reaction requiring the presence of ATP</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of granules opacity</measure>
    <time_frame>Baseline (M0)</time_frame>
    <description>Delta granules contain calcium, which makes them naturally opaque to electrons and thus allows their direct visualization in electronic microscopy.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of granules opacity</measure>
    <time_frame>at 6 months</time_frame>
    <description>Delta granules contain calcium, which makes them naturally opaque to electrons and thus allows their direct visualization in electronic microscopy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemorrhagic risk assessment</measure>
    <time_frame>Baseline (M0)</time_frame>
    <description>Evaluation using the ISTH score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Typage of delta granules anomalies</measure>
    <time_frame>At 6 months</time_frame>
    <description>Fib-SEM technic by focussed ion beam scanning which allows a 3D reconstitution of the platelets and thus to visualize any empty granules</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Genetic anomalies of delta granules</measure>
    <time_frame>At 6 months</time_frame>
    <description>Sequencing on a broad set of genes involved in platelet function. Bioinformatic analysis is carried out using BWA-MEM software (Alignment on the genome version HG19)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin consumption</measure>
    <time_frame>Baseline (M0)</time_frame>
    <description>Evaluated by% of residual Thrombin after plasma coagulation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prothrombin consumption</measure>
    <time_frame>at 6 months</time_frame>
    <description>Evaluated by% of residual Thrombin after plasma coagulation</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">480</enrollment>
  <condition>Spontaneous Induced Unexplained Haemorrhagic</condition>
  <arm_group>
    <arm_group_label>Children and adults with unexplained hemorrhagic syndrome</arm_group_label>
    <description>Patients with spontaneous or induced hemorrhagic manifestations who are present for a consultation to investigate a thrombopathy or during follow-up consultations as part of their usual care.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Haemostasis consultation</intervention_name>
    <description>Haemostasis consultation</description>
    <arm_group_label>Children and adults with unexplained hemorrhagic syndrome</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Standard management of patients suspected of thrombopathy</intervention_name>
    <description>Standard management of patients suspected of thrombopathy</description>
    <arm_group_label>Children and adults with unexplained hemorrhagic syndrome</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients addressed to the specialized haemostasis consultations of the various services
        associated with the project for the exploration of haemorrhagic symptomatology referring to
        a primary haemostasis anomaly.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult or child patient ≥ 2 years

          -  Having a hemorrhagic score ISTH &gt; 3 for men, &gt; 5 for women and &gt; 2 for children.

          -  With no abnormal coagulation (defined by normal TP and TCK or activity ≥ 50% of FII,
             FV, FVII, FX, FVIII, FIX, FXI)

          -  no deficiency of Willebrand factor (defined by a cofactor activity with Ristoctin
             (VWF: RCo &lt; 50%))

          -  no a known major thrombocytopenia/thrombopathy linked to a deficiency of one of the
             major platelet receptors

          -  Information of the patient and/or his legal representative present

        Exclusion Criteria:

          -  Inability or refusal of compliance with research requirements

          -  Thrombocytopenia &lt; 100 G/L

          -  Treatments interfering with platelet functions within 10 days prior to inclusion

          -  Malignant hemopathy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Delphine BORGEL, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Delphine BORGEL, PhD</last_name>
    <phone>0033171196091/0033144495111</phone>
    <email>delphine.borgel@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nelly BRIAND, PhD</last_name>
    <phone>+33 1 44 38 18 62</phone>
    <email>nelly.briand@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker Enfants Malades - AP-HP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie-Christine ALESSI, PHD</last_name>
      <phone>00 33 4 91 32 45 06</phone>
      <email>marie-christine.alessi@univ-amu.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <reference>
    <citation>Gresele P, Harrison P, Bury L, Falcinelli E, Gachet C, Hayward CP, Kenny D, Mezzano D, Mumford AD, Nugent D, Nurden AT, Orsini S, Cattaneo M. Diagnosis of suspected inherited platelet function disorders: results of a worldwide survey. J Thromb Haemost. 2014 Sep;12(9):1562-9. doi: 10.1111/jth.12650. Epub 2014 Jul 25.</citation>
    <PMID>24976115</PMID>
  </reference>
  <reference>
    <citation>Quiroga T, Goycoolea M, Panes O, Aranda E, Martínez C, Belmont S, Muñoz B, Zúñiga P, Pereira J, Mezzano D. High prevalence of bleeders of unknown cause among patients with inherited mucocutaneous bleeding. A prospective study of 280 patients and 299 controls. Haematologica. 2007 Mar;92(3):357-65.</citation>
    <PMID>17339185</PMID>
  </reference>
  <reference>
    <citation>Fiore M, Garcia C, Sié P, et al. δ-storage pool disease: an underestimated cause of unexplained bleeding. Hématologie 2017-8; 243-254.</citation>
  </reference>
  <reference>
    <citation>Gresele P; Subcommittee on Platelet Physiology of the International Society on Thrombosis and Hemostasis. Diagnosis of inherited platelet function disorders: guidance from the SSC of the ISTH. J Thromb Haemost. 2015 Feb;13(2):314-22. doi: 10.1111/jth.12792. Epub 2015 Jan 22. Review.</citation>
    <PMID>25403439</PMID>
  </reference>
  <reference>
    <citation>Mumford AD, Frelinger AL 3rd, Gachet C, Gresele P, Noris P, Harrison P, Mezzano D. A review of platelet secretion assays for the diagnosis of inherited platelet secretion disorders. Thromb Haemost. 2015 Jul;114(1):14-25. doi: 10.1160/TH14-11-0999. Epub 2015 Apr 16. Review.</citation>
    <PMID>25879272</PMID>
  </reference>
  <reference>
    <citation>Selle F, James C, Tuffigo M, Pillois X, Viallard JF, Alessi MC, Fiore M. Clinical and Laboratory Findings in Patients with δ-Storage Pool Disease: A Case Series. Semin Thromb Hemost. 2017 Feb;43(1):48-58. doi: 10.1055/s-0036-1584568. Epub 2016 Jun 15.</citation>
    <PMID>27304079</PMID>
  </reference>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>June 18, 2019</study_first_submitted>
  <study_first_submitted_qc>September 17, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 19, 2019</study_first_posted>
  <last_update_submitted>March 29, 2020</last_update_submitted>
  <last_update_submitted_qc>March 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dense platelet granules</keyword>
  <keyword>Thrombopathy</keyword>
  <keyword>Hemorrhagic symptomatology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Congenital Abnormalities</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

